<DOC>
	<DOC>NCT00689728</DOC>
	<brief_summary>The purpose of this study is to explore whether LY2127399 is effective in relieving signs and symptoms of RA in patients with a history of inadequate response or intolerance to at least 1 TNFα inhibitor therapy. Examples of these TNFα inhibitor therapies that are currently on the market include Enbrel® (etanercept), Remicade® (infliximab), and Humira® (adalimumab).</brief_summary>
	<brief_title>A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Have given written informed consent approval Women must not be at risk to become pregnant during study participation Diagnosis of Rheumatoid Arthritis Active Rheumatoid Arthritis Current, regular use of Methotrexate, at a stable dose Have been on at least 1 biologic TNFα inhibitor therapy and either failed or were intolerant to treatment Other criteria to be reviewed by study doctor Use of excluded medications (reviewed by study doctor) Have medical findings which, in the opinion of the study doctor, put patient at an unacceptable risk for participation in the study Have had recent or ongoing infection which, in the opinion of the study doctor put patient at an unacceptable risk for participation Evidence of tuberculosis Have systemic inflammatory condition other than RA, such as juvenile RA, seronegative spondyloarthropathy, Crohn's disease, ulcerative colitis, or psoriatic arthritis. Other criteria to be reviewed by study doctor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>